BPC-157 in Adults 65 and Older: Evidence and Dosing Gaps

Is there a BPC-157 dose for people over 65?

No. BPC-157 is not an FDA-approved drug and no approved product contains it, so there is no approved dose for any age group [3]. The amounts that appear in the literature are the doses used in a handful of small human reports; none was established as a recommended regimen [3].

Those amounts were: a rectal enema of up to 2 mg per kg daily for 8 days in healthy volunteers and 80 mg daily for 2 weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice for knee pain; 10 mg injected around the bladder wall once for interstitial cystitis; and 10 mg followed by 20 mg given intravenously on two days to two healthy adults [3]. FDA's review of these reports noted that dose-response relationships for the reported protective effects were not established [3].

The bladder-pain pilot included women aged 39 to 76 [1], and the two-person intravenous pilot included a 68-year-old woman [2]. Neither compared an older group with a younger one. The available reports do not establish how many participants overall were 65 or older.

How old were the people actually studied?

The 2026 systematic review of human BPC-157 evidence in orthopaedic and regenerative use found three studies with 30 patients in total, judged all three to be of poor methodological quality, and rated overall certainty of evidence as very low [4]. The knee-pain chart review enrolled 17 people, and 16 were reached for follow-up by phone [8]. The bladder-pain pilot included 12 women and the intravenous pilot included 2 adults [1][2].

Ages appear in two of them. The interstitial cystitis pilot enrolled 12 women aged 39 to 76, with a mean age of 58.3 [1]. The intravenous pilot enrolled two adults, a 58-year-old man and a 68-year-old woman [2].

The ages reported in these studies stop at 76, and no results by age group are described.

What is missing in pharmacokinetics

No human data establish whether BPC-157 dosing should change with body weight, age or kidney function. FDA found no human pharmacokinetic data for BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [3]. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged that it appears not to be absorbed systemically by that route [3].

Without measurements of how much of the peptide reaches the bloodstream and how long it stays there, a dose scaled by body weight, age or kidney function would rest on assumptions rather than on human measurements.

Does kidney function change the dose?

Nothing in the human data connects kidney function to BPC-157 exposure by the routes people use. An eGFR describes how well the kidneys filter; no human measurement links it to BPC-157 clearance, for which there are no data by the oral, subcutaneous, nasal or topical routes [3].

The animal data that do exist are toxicity signals, not dosing guidance. In 28-day intramuscular studies BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [3]. FDA described BPC-157's molecular targets as unidentified and its mechanisms as poorly understood [3].

What safety information exists?

FDA searched its adverse-event database through December 4, 2025 and found three reports, all involving injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 product sold for research. FDA said it cannot tell whether BPC-157 caused these events [3].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small and gave limited safety information [3]. FDA concluded there is insufficient clinical safety information to characterize BPC-157's safety profile [3].

Is compounded BPC-157 legal?

BPC-157 is not on the list of bulk substances FDA says it generally will not act against compounders for, and it is not on FDA's list for outsourcing facilities [5][9]. It sat in category 2, the significant-safety-risk group, from September 2023 until April 22, 2026, then moved to a 'nominated but withdrawn' table after the groups that nominated it withdrew. Removal was not a finding of safety, and FDA's stated concerns remain on that page: possible immunogenicity for certain routes of administration, peptide-related impurities and characterization problems, and the statement that FDA 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [10].

On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation. Its vote is advice only and does not add the substance to the list; adding it would need formal rulemaking [11]. FDA's own reviewers had proposed that it not be added, citing poor chemical characterization, little safety and immunogenicity information, insufficient evidence for ulcerative colitis, and the existence of approved drugs for that condition [3].

On October 28, 2026 HHS filed a notice of a draft enforcement-discretion policy covering six peptides including BPC-157, scheduled for Federal Register publication on October 30, 2026. Under the draft, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with BPC-157 acetate in subcutaneous, intramuscular, oral or topical forms if conditions are met, among them a single active ingredient, bulk substance from an FDA-registered manufacturer with a valid certificate of analysis, a patient-specific prescription, and MedWatch reporting of serious adverse events and quality problems [6][12]. The notice states that the policy does not establish rights and is not binding on HHS or the public, and it is not an FDA approval [6]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [9].

Does BPC-157 appear on anti-doping lists?

Yes. WADA names BPC-157 in class S0, non-approved substances, and it is prohibited at all times, in and out of competition. It was first named under S0 in the 2022 List and is still named in the 2026 List, in force since January 1, 2026 [7][13].